Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) considers it can fund capital requirements and operations well into 2019. As of the close of September 30, 2017, the firm posted cash and cash equivalent of $66.3 million. An additional net proceeds of $3 million from shares offered in September and October 2017 as per its ATM plan was recorded in Q4 2017.
Cannabinoids marks as a class of chemical compounds seen in the Cannabis crop. The two main cannabinoids comprised in Cannabis are cannabidiol and ∆9-tetrahydrocannabinol. Preclinical and clinical data support the prospect for Hemp in curing epilepsy, FXS and other neuropsychiatric problem while THC can help cure tics.
Zynerba Pharmaceuticals is advancing therapeutic drugs that use unique transdermal know-hows that, if successful, may enable for controlled and sustained delivery of therapeutic levels of THC and Hemp. Transdermal supply of cannabinoids may have gains over oral dosing as it enables the drug to be absorbed via the skin straight into the bloodstream.
This averts first-pass liver metabolism, probably allowing reduced dosage levels of active pharma ingredients with an increased bioavailability and enhanced safety profile. Transdermal delivery even avoids the gastrointestinal tract, reducing the opportunity for GI linked adverse events and the prospective degradation of Cannabidiol by gastric acid into ∆9-tetrahydrocannabinol, which may be linked with undesired psychoactive effects. Utilizing an established chemical pharma procedure for manufacturing, Zynerba Pharmaceuticals replicates the THC and Hemp found in the Cannabis crop.
They consider that this will enable them to meet stringent international regulatory agencies’ standards while guaranteeing that they can efficiently supply the quantity of product required to fulfill the demand of the markets that the company is targeting.
In the last trading session, the stock price of Zynerba Pharmaceuticals declined more than 1% to close the day at $11.74. Post the last decline, the market cap of firm was noted at $159.12 million.